Celltrion USA signs agreement with Express Scripts for Zymfentra

South Korean Celltrion (Kosdaq: 068270) saw its shares lifted 4% to 183,700 won today, after it announced that its US subsidiary has signed an agreement with Express Scripts, one of the nation's leading pharmacy benefit managers (PBMs) negotiating on behalf of health plans covering more than 100 million people.

The agreement, effective April 4, 2024 provides Zymfentra (infliximab-dyyb) preferred brand access on the Express Scripts National Preferred Formulary serving 21.9 million insured lives. Express Scripts provides plan participants such as Health Plans of the pharmacy benefit manager (PBM) the ability to add Zymfentra to its formularies.

"This agreement opens up an important pathway for access to treatment for millions of patients with chronic diseases," said Francine Galante, vice president of market access at Celltrion USA. "We will continue to work with providers, patients and physicians to build upon our mission of developing transformational therapies that meet the needs of our patients living with chronic debilitating pain," she added.